Accelerate Diagnostics Total Liabilities

Accelerate Diagnostics (AXDX) currently reports a total liabilities of $85M as of December 2024. That compares with $51M in the prior-year period — up 65.1% year over year. Use the charts on this page to explore Accelerate Diagnostics's total liabilities history and peer comparisons.

Accelerate Diagnostics's total liabilities increased from $51M to $85M — a 65.1% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Accelerate Diagnostics reported $85M in total liabilities as of December 2024. That compares with $51M in the prior-year period — up 65.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $85M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Accelerate Diagnostics, and consider following AXDX for alerts when major investors trade the stock.

Accelerate Diagnostics is classified in the Healthcare sector. On total liabilities, it currently shows $85M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AXDX with unrelated industries.